Nektar Therapeutics (NKTR) Research & Development (2010 - 2026)

Nektar Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• On a quarterly basis, Research & Development rose 17.06% year-over-year to $35.7 million in Q1 2026; TTM through Mar 2026 was $122.5 million, a 1.17% decrease from a year earlier, with the FY2025 full-year figure at $117.3 million, down 2.96% from the prior year.
• Research & Development improved to $35.7 million in Q1 2026 per NKTR's latest filing, from $29.7 million in the prior quarter.
• Across five years, Research & Development topped out at $107.3 million in Q1 2022 and bottomed at $24.1 million in Q3 2023.
• The 5-year median for Research & Development is $29.9 million (2023), against an average of $35.7 million.
• Across the five-year window, Research & Development tumbled 71.59% in 2023 and soared 45.54% in 2024, its largest moves.
• Year by year, Research & Development stood at $34.7 million in 2022, then fell by 13.81% to $29.9 million in 2023, then dropped by 4.0% to $28.7 million in 2024, then rose by 3.36% to $29.7 million in 2025, then climbed by 20.09% to $35.7 million in 2026.
• Per Business Quant, the three latest NKTR Research & Development figures stand at $35.7 million (Q1 2026), $29.7 million (Q4 2025), and $27.3 million (Q3 2025).